Consequently, PD-L1 inhibition with the ABNF-bispecific Nanofitin, due to its small size and high tumor specificity, offers an effective strategy for bypassing both the target sink and on-target/off-tumor effects, thereby enhancing the therapeutic window of this therapy. Here, CD274 is linked to neoplasm.